Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French

Item

http://www.wikidata.org/entity/Q51697267

Q51697267

about

CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial.Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer.Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

P2860

Q37592211-46685FE9-D438-4295-BAA1-11659895A61E Q38765017-B900C159-F217-49F5-AD21-112602D7CA21 Q57280932-189E2450-8AB7-4D33-84BF-7B85BC2429E2

P2860

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French

Item

http://www.wikidata.org/entity/Q51697267

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Randomized phase 2 neoadjuvant ...... he UNICANCER CARMINA 02 French

@en

Randomized phase 2 neoadjuvant ...... he UNICANCER CARMINA 02 French

@nl

type

Item

label

Randomized phase 2 neoadjuvant ...... he UNICANCER CARMINA 02 French

@en

Randomized phase 2 neoadjuvant ...... he UNICANCER CARMINA 02 French

@nl

prefLabel

Randomized phase 2 neoadjuvant ...... he UNICANCER CARMINA 02 French

@en

Randomized phase 2 neoadjuvant ...... he UNICANCER CARMINA 02 French

@nl

P1476

Randomized phase 2 neoadjuvant ...... he UNICANCER CARMINA 02 French

@en

P2093

Anne-Laure Martin

http://www.w3.org/2001/XMLSchema#string

Brigitte Sigal

http://www.w3.org/2001/XMLSchema#string

Corinne Balleyguier

http://www.w3.org/2001/XMLSchema#string

Céline Bourgier

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Mouret-Fourme

http://www.w3.org/2001/XMLSchema#string

Fabienne Thibault

http://www.w3.org/2001/XMLSchema#string

Florence Lerebours

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Nabholz

http://www.w3.org/2001/XMLSchema#string

Jerome Lemonnier

http://www.w3.org/2001/XMLSchema#string

Laurence Venat-Bouvet

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

P304

3032-3040

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.30143

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27315583

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French

about

P2860

P2860

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921